Infinity to Present at New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021

Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) announces a presentation summarizing recent clinical data on eganelisib, a potential first-in-class oral immuno-oncology therapy. The event will occur during the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021 virtual symposium from May 12-14, 2021. The presentation titled 'Eganelisib Activity as a Macrophage Reprogramming Therapeutic' will be held on May 12 at 1:26 pm ET. Attendees can access the presentation on Infinity's website, available for 30 days post-event.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that the Company will have a presentation summarizing recent eganelisib clinical data will be followed by a Q&A session at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021 virtual symposium taking place on May 12-14, 2021.

Presentation Details:

Title:			Eganelisib (IPI-549) Activity as a Macrophage Reprogramming Therapeutic Candidate in 1L Metastatic TNBC, 2L Metastatic Urothelial Cancer and Other Solid Tumors
Date:			Wednesday, May 12
Time:			1:26 pm Eastern Time

The presentation can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin^® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil^® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin^® is a registered trademark of Genentech, Inc.
Doxil^® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005307/en/

FAQ

What is the significance of the upcoming Infinity Pharmaceuticals presentation?

Infinity Pharmaceuticals will present recent clinical data on eganelisib during the New York Academy of Sciences virtual symposium from May 12-14, 2021.

When will the Infinity Pharmaceuticals eganelisib presentation take place?

The presentation by Infinity Pharmaceuticals is scheduled for May 12, 2021, at 1:26 pm Eastern Time.

Where can I find the Infinity Pharmaceuticals eganelisib presentation?

The presentation can be accessed on Infinity Pharmaceuticals' website and will be available for 30 days after the event.

What is eganelisib and its role in oncology?

Eganelisib is a potential first-in-class oral immuno-oncology therapy developed by Infinity Pharmaceuticals, focusing on macrophage reprogramming to combat immune suppression in cancer.

How does eganelisib fit into Infinity Pharmaceuticals' clinical studies?

Infinity Pharmaceuticals is evaluating eganelisib in various studies, including combinations with other therapies for advanced cancers such as TNBC and urothelial cancer.